Head-to-head evidence
regor GLP-1 vs ZT002
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
regor GLP-1
Developed by Regor Pharmaceuticals
NCT06867718 · Phase 2 · completed
The trial randomized 267 participants to four active-dose groups or placebo and masked both participants and investigators. Its primary endpoint was percent change in body weight at Week 36, but the registry does not report whether the comparison met its statistical objective, so the evidence is currently limited to a well-controlled study design with an unknown result.
ZT002
Developed by Beijing QL Biopharmaceutical
NCT07020884 · Phase 2 · completed
This randomized, double-blind, placebo-controlled Phase 2 trial (n=303) in adults with overweight or obesity found that ZT002 produced significantly greater weight loss than placebo at 24 weeks across all doses tested, up to 14.4% versus 2.4% with placebo (p<0.0001).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT07443059 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: regor GLP-1's landscape · ZT002's landscape